BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©Author(s) (or their employer(s)) 2026.
World J Gastroenterol. Mar 14, 2026; 32(10): 116152
Published online Mar 14, 2026. doi: 10.3748/wjg.v32.i10.116152
Table 4 Adverse events during percutaneous transhepatic biliary drainage, sinus tract dilation as well as percutaneous transhepatic cholangioscopy-assisted procedures, n (%)

PTBD (n = 40)
Percutaneous sinus tract dilation (n = 40)
PTCS-assisted anastomotic stricture dilation (n = 31)1
PTCS-assisted anastomotic recanalization (n = 8)
PTCS-assisted stone therapy (n = 36)2
Cholangitis5 (12.5)2 (5.0)2 (6.5)0 (0.0)2 (5.6)
Bacteremia4 (10.0)2 (5.0)1 (3.3)0 (0.0)0 (0.0)
Right pleural effusion2 (5.0)1 (2.5)0 (0.0)0 (0.0)0 (0.0)
Hemobilia0 (0.0)1 (2.5)31 (3.3)0 (0.0)0 (0.0)
Catheter migration0 (0.0)1 (2.5)40 (0.0)0 (0.0)1 (2.8)4
Overall11 (27.5)7 (17.5)4 (12.9)0 (0.0)3 (8.3)


Write to the Help Desk